Allspring Global Investments Holdings LLC Buys 2,613,482 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Allspring Global Investments Holdings LLC grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 1,144.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,841,849 shares of the biotechnology company's stock after purchasing an additional 2,613,482 shares during the period. Allspring Global Investments Holdings LLC owned about 1.20% of ADMA Biologics worth $51,016,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ADMA. Hollencrest Capital Management bought a new stake in ADMA Biologics during the third quarter worth about $30,000. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the 3rd quarter valued at $31,000. GAMMA Investing LLC raised its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares during the last quarter. National Bank of Canada FI acquired a new position in ADMA Biologics in the third quarter worth $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics in the 3rd quarter valued at about $62,000. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Trading Down 1.1 %

Shares of ADMA Biologics stock traded down $0.18 during trading on Monday, hitting $15.90. 1,740,737 shares of the company were exchanged, compared to its average volume of 2,383,370. The firm has a market capitalization of $3.76 billion, a P/E ratio of 56.79 and a beta of 0.75. The firm's fifty day moving average price is $17.21 and its 200 day moving average price is $17.87. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1-year low of $5.02 and a 1-year high of $23.64.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ADMA shares. Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. HC Wainwright upped their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

Insider Buying and Selling

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.